ARK Genomic Revolution ETF Newsroom

Schrodinger Analyst Ratings

BenzingaJul 3 01:02

Leerink Partners Initiates Coverage On Schrodinger With Outperform Rating, Announces Price Target of $29

BenzingaJul 3 01:02

Buy Rating for Arcturus Therapeutics: Advancing Clinical Programs and Strengthening Safety Profile

TipRanksJul 2 19:03

Piper Sandler Keeps Their Buy Rating on Arcturus Therapeutics (ARCT)

TipRanksJul 2 18:45

HC Wainwright & Co. Reiterates Buy on Arcturus Therapeutics, Maintains $60 Price Target

BenzingaJul 2 18:27

Arcturus Therapeutics Analyst Ratings

BenzingaJul 2 18:27

Buy Rating Affirmed: Promising Developments in Arcturus Therapeutics' MRNA Treatments for Rare Diseases

TipRanksJul 2 18:25

Twist Bioscience Analyst Ratings

BenzingaJun 29 00:03

RBC Capital Maintains Outperform on Nurix Therapeutics, Raises Price Target to $26

BenzingaJun 27 22:32

Nurix Therapeutics Analyst Ratings

BenzingaJun 27 22:32

Canaccord Genuity Maintains Buy on Intellia Therapeutics, Maintains $73 Price Target

BenzingaJun 27 21:39

Intellia Therapeutics Analyst Ratings

BenzingaJun 27 21:38

Ionis Pharmaceuticals Analyst Ratings

BenzingaJun 27 20:22

Needham Reiterates Buy on CRISPR Therapeutics, Maintains $88 Price Target

BenzingaJun 27 17:37

CRISPR Therapeutics Analyst Ratings

BenzingaJun 27 17:35

Needham Reiterates Buy on Recursion Pharmaceuticals, Maintains $17 Price Target

BenzingaJun 25 19:47

Recursion Pharmaceuticals Analyst Ratings

BenzingaJun 25 19:45

Intellia Therapeutics Analyst Ratings

BenzingaJun 25 01:35

Truist Securities Maintains Buy on Intellia Therapeutics, Maintains $120 Price Target

BenzingaJun 25 01:35

Cantor Fitzgerald Reiterates Overweight on Intellia Therapeutics, Maintains $65 Price Target

BenzingaJun 18 22:13